RECENT DEVELOPMENTS
CDI was the first company
worldwide to commercially
launch an iPSC-derived product,
entering the market with iCell
Cardiomyocytes, or human heart
cells, in early 2010. Over the
past two years, CDI has launched
additional human cell-specific
products including iCell Neurons
(
brain cells) and iCell Endothelial
Cells (blood vessel cells) for
toxicity testing, drug discovery
and disease modeling. A fourth
cell type, iCell Hepatocytes (liver
cells), is currently in the pre-
commercial stage but has been
shipping to customers due to
market demand.
This June the company
iCell Cardiom Actin M
Cellular Dynamics International
Revolut
Visit us online at
